Imlunestrant improved PFS in ESR1-mutated breast cancer compared to standard endocrine therapy, but not significantly in the overall population. Combining imlunestrant with Verzenio enhanced PFS in ...
Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.
image: Mafalda Oliveira, Senior Consultant at the Vall d’Hebron University Hospital’s Medical Oncology Department and Clinical Investigator of the Vall d’Hebron Institute of Oncology’s (VHIO) Breast ...
– Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results